Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis
Primary systemic immunoglobulin light chain (AL) amyloidosis is caused by a plasma cell clone of, usually low, malignant potential that expresses CD38 molecules on their surface. Treatment of AL amyloidosis is based on the elimination of the plasma cell clone. The combination of cyclophosphamide–bor...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
SAGE Publishing
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/b193029987d6402aaadfdebb29ef976c |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|